Stannsoporfin

DRUG5 trials

Sponsors

InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company

Conditions

Hyperbilirubinemia, NeonatalJaundiceJaundice, NeonatalNeonatal HyperbilirubinemiaNutritional and Metabolic Diseases

Phase 2

A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia

TerminatedNCT00850993

InfaCare Pharmaceuticals Corporation, a Mallinckrodt CompanyHyperbilirubinemia, Neonatal

Start: 2008-08-31End: 2012-05-31Updated: 2019-10-30

Stannsoporfin With Light Therapy for Newborn Babies With Jaundice

CompletedNCT01887327

InfaCare Pharmaceuticals Corporation, a Mallinckrodt CompanyHyperbilirubinemia, Neonatal, Jaundice, Neonatal

Start: 2013-10-16End: 2016-03-22Updated: 2020-02-06

Phase 3

Efficacy and Safety of Stannsoporfin in Neonates

CompletedNCT02685137

InfaCare Pharmaceuticals Corporation, a Mallinckrodt CompanyNutritional and Metabolic Diseases

Start: 2002-05-01End: 2013-02-28Updated: 2019-10-29

Unknown Phase

Follow up Study of Patients Having Participated in Clinical Trial 64,185-204

CompletedNCT02000830

InfaCare Pharmaceuticals Corporation, a Mallinckrodt CompanyHyperbilirubinemia, Neonatal

Start: 2013-10-17End: 2020-02-28Updated: 2021-02-02

Observational Follow-up of Participants From Clinical Trial 64,185-202 (NCT00850993)

CompletedNCT02033096

InfaCare Pharmaceuticals Corporation, a Mallinckrodt CompanyJaundice, Neonatal Hyperbilirubinemia

Start: 2008-10-20End: 2015-11-09Updated: 2019-10-15

Related Papers

Stannsoporfin with phototherapy to treat hyperbilirubinemia in newborn hemolytic disease.

2021-10-118 citations